Belite Bio (BLTE) Current Assets (2021 - 2026)
Belite Bio (BLTE) posted quarterly Current Assets of $521.9 million for Q1 2026, up 227.62% year-over-year from $159.3 million in Q1 2025, and up 5.58% quarter-over-quarter from $494.3 million in Q4 2025.
Belite Bio (BLTE) Current Assets (2021 - 2026) Analysis & Trends
Belite Bio's Current Assets history runs 6 years deep, the most recent figure standing at $521.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 227.62% year-over-year to $521.9 million; the TTM figure through Mar 2026 stood at $521.9 million (up 227.62% YoY), while the FY2025 annual figure was $494.3 million, up 236.07% from the prior year.
- Current Assets for Q1 2026 stood at $521.9 million, up from $494.3 million in the prior quarter.
- The five-year high for Current Assets was $521.9 million in Q1 2026, with the low at $38.4 million in Q1 2023.
- The 5-year median for Current Assets is $112.6 million (2024), against an average of $168.5 million.
- Peak annual rise in Current Assets reached 236.07% in 2025, while the deepest fall reached 32.59% in 2025.
- Belite Bio's Current Assets stood at $42.8 million in 2022, then surged by 110.11% to $89.9 million in 2023, then jumped by 63.52% to $147.1 million in 2024, then soared by 236.07% to $494.3 million in 2025, then increased by 5.58% to $521.9 million in 2026.
- Business Quant data shows BLTE's Current Assets at $521.9 million in Q1 2026, $494.3 million in Q4 2025, and $277.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 521.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 521.86 Mn |
| Dec 31, 2025 | 494.27 Mn |
| Sep 30, 2025 | 277.21 Mn |
| Jun 30, 2025 | 150.97 Mn |
| Mar 31, 2025 | 159.29 Mn |
| Dec 31, 2024 | 147.07 Mn |
| Sep 30, 2024 | 111.27 Mn |
| Jun 30, 2024 | 113.86 Mn |
| Mar 31, 2024 | 96.47 Mn |
| Dec 31, 2023 | 89.94 Mn |
| Sep 30, 2023 | 56.14 Mn |
| Jun 30, 2023 | 59.14 Mn |
| Mar 31, 2023 | 38.42 Mn |
| Dec 31, 2022 | 42.81 Mn |
| Dec 31, 2021 | 17.43 Mn |